J. S. Lee

Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022

A. Monto, B. Flannery, E. Belongia, 2022, medRxiv.

Equipment-free detection of SARS-CoV-2 and Variants of Concern using Cas13

Tinna-Solveig F. Kosoko-Thoroddsen, Pardis C Sabeti, C. Happi, 2021, medRxiv.

Long-term outcomes of hospitalized SARS-CoV-2/COVID-19 patients with and without neurological involvement: 3-year follow-up assessment

M. Mehler, D. Altschul, T. Duong, 2023, medRxiv.

Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines

H. Zar, G. Alter, D. Zavadska, 2022, Cell Reports Medicine.

Peginterferon alfa‐2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

K. Reddy, C. Howell, L. Jeffers, 2006, Journal of viral hepatitis.

Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults

S. Cramer, S. Klein, M. Betenbaugh, 2022, medRxiv.

Radiographic Assessment of Lung Edema (RALE) Scores are Highly Reproducible and Prognostic of Clinical Outcomes for Inpatients with COVID-19

C. Kessinger, C. Girard, G. Kitsios, 2022, medRxiv.

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial

Y. K. Kim, A. Walls, D. Veesler, 2022, medRxiv.

Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.

S. Aung, W. Aung, P. W. Ei, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

A meta-analysis of genome-wide association studies in 614,243 individuals identifies 59 novel susceptibility loci underlying Dupuytren's contracture

Jacob F. Degner, J. Waring, Finngen, 2022, medRxiv.

Lower respiratory tract myeloid cells harbor SARS-CoV-2 and display an inflammatory phenotype

Simon C Watkins, D. Stolz, P. Bjorkman, 2020, medRxiv.